Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (278)	7/24/2001 2:57:36 PM
From: tuck	Respond to of 1005

INGN has had good news today, but is trading around BLUE HP's buy price, down some for the day. Tempted to get a little in real life. I did nibble some MCLS and PTIE today. BLUE HP is looking for $6 on the latter; didn't make the decision until the drop below that was gone. Tomorrow may do it. Also in real life, sold my GNVC. BLUE HP will hold: I still like the stock. I sold for my own portfolio reasons, and may well get back in on weakness. A busy day for me; I'll update my ownership disclosure soon. >>AUSTIN, Texas, Jul 24, 2001 /PRNewswire via COMTEX/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN chart, msgs) announced today that it has been awarded the manufacturing project to produce the adenoviral reference material to be used by companies and academic institutions developing adenovirus-based products. Two competitive awards were granted to Introgen from the Adenoviral Reference Material Working Group of the Williamsburg BioProcessing Foundation, who acted as the facilitator for the Working Group. The Office of Cellular and Gene Therapies of the Federal Food and Drug Administration (FDA) advised on the award grants based on competencies and expertise of the applicants. A number of companies and institutions submitted proposals for the project. Introgen will manufacture the adenoviral reference material using its patented manufacturing processes to purify and produce approximately 5000 vials of adenovirus reference material. The vials will be stored at the American Type Culture Collection (ATCC), a repository for biological materials. "Introgen is pleased to have successfully competed for a project that represents an industry wide effort to create a common reference material," said Shawn L. Gallagher, vice president for product development. "Introgen has proven expertise in the production of adenovirus having supplied clinical materials for 20 clinical trials on three continents including pivotal Phase III studies. The industry overall will benefit from the reference material in that the potency of products can be more readily assessed by the FDA, and it will provide a standard of comparison for academic institutions and industrial companies using adenovirus in the development of gene therapies, vaccines and other products."<< snip Cheers, Tuck

To: tuck who wrote (278)	7/24/2001 3:42:20 PM
From: tom pope	Read Replies (2) \| Respond to of 1005

This is Marketwatch's take, Tuck: >>Arena Pharmaceuticals (ARNA: news, chart, profile) shares plunged 20 percent Tuesday morning after the company posted a second-quarter loss, while analysts were looking for a profit. The company reported losses of $2.1 million, or 9 cents per share, excluding charges, less than losses of 21 cents per share in the year-earlier period. However, analysts had been expecting the company to turn a profit of 2 cents a share. Revenue increased 158 percent over last year to $3.3 million.